Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 203, doi. 10.1002/cpdd.728
- By:
- Publication type:
- Article
Works matching IS 2160763X AND DT 2020 AND VI 9 AND IP 2
Results: 14
1
2
A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid Receptor.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 256, doi. 10.1002/cpdd.721
- By:
- Publication type:
- Article
3
Why Collecting Pharmacokinetic Information After Intravenous Drug Administration Is Important.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 146, doi. 10.1002/cpdd.763
- By:
- Publication type:
- Article
4
Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 246, doi. 10.1002/cpdd.738
- By:
- Publication type:
- Article
5
Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 224, doi. 10.1002/cpdd.737
- By:
- Publication type:
- Article
6
Effect of Food on the Pharmacokinetics of Quizartinib.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 277, doi. 10.1002/cpdd.770
- By:
- Publication type:
- Article
7
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 214, doi. 10.1002/cpdd.723
- By:
- Publication type:
- Article
8
Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 189, doi. 10.1002/cpdd.740
- By:
- Publication type:
- Article
9
Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 267, doi. 10.1002/cpdd.717
- By:
- Publication type:
- Article
10
Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 235, doi. 10.1002/cpdd.706
- By:
- Publication type:
- Article
11
Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 151, doi. 10.1002/cpdd.699
- By:
- Publication type:
- Article
12
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 162, doi. 10.1002/cpdd.690
- By:
- Publication type:
- Article
13
Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C‐Reactive Protein in Hospitalized Patients With Gram‐Positive Infections.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 175, doi. 10.1002/cpdd.684
- By:
- Publication type:
- Article
14
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 141, doi. 10.1002/cpdd.676
- Publication type:
- Article